NO20003960L - Salts of paroxsetine - Google Patents

Salts of paroxsetine

Info

Publication number
NO20003960L
NO20003960L NO20003960A NO20003960A NO20003960L NO 20003960 L NO20003960 L NO 20003960L NO 20003960 A NO20003960 A NO 20003960A NO 20003960 A NO20003960 A NO 20003960A NO 20003960 L NO20003960 L NO 20003960L
Authority
NO
Norway
Prior art keywords
paroxsetine
salts
hypophosphoric
methylbenzenesulfonic
paroxetine
Prior art date
Application number
NO20003960A
Other languages
Norwegian (no)
Other versions
NO20003960D0 (en
Inventor
David Crowe
Deirdre O'keeffe
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802658.6A external-priority patent/GB9802658D0/en
Priority claimed from GBGB9802665.1A external-priority patent/GB9802665D0/en
Priority claimed from GBGB9802639.6A external-priority patent/GB9802639D0/en
Priority claimed from GBGB9802657.8A external-priority patent/GB9802657D0/en
Priority claimed from GBGB9802645.3A external-priority patent/GB9802645D0/en
Priority claimed from GBGB9802664.4A external-priority patent/GB9802664D0/en
Priority claimed from GBGB9802661.0A external-priority patent/GB9802661D0/en
Priority claimed from GBGB9802656.0A external-priority patent/GB9802656D0/en
Priority claimed from GBGB9802654.5A external-priority patent/GB9802654D0/en
Priority claimed from GBGB9802644.6A external-priority patent/GB9802644D0/en
Priority claimed from GBGB9802638.8A external-priority patent/GB9802638D0/en
Priority claimed from GBGB9802659.4A external-priority patent/GB9802659D0/en
Priority claimed from GBGB9802646.1A external-priority patent/GB9802646D0/en
Priority claimed from GBGB9802698.2A external-priority patent/GB9802698D0/en
Priority claimed from GBGB9802640.4A external-priority patent/GB9802640D0/en
Priority claimed from GBGB9802655.2A external-priority patent/GB9802655D0/en
Priority claimed from GBGB9802653.7A external-priority patent/GB9802653D0/en
Priority claimed from GBGB9817364.4A external-priority patent/GB9817364D0/en
Priority claimed from GBGB9817307.3A external-priority patent/GB9817307D0/en
Priority claimed from GBGB9817309.9A external-priority patent/GB9817309D0/en
Priority claimed from GBGB9817344.6A external-priority patent/GB9817344D0/en
Priority claimed from GBGB9817359.4A external-priority patent/GB9817359D0/en
Priority claimed from GBGB9817321.4A external-priority patent/GB9817321D0/en
Priority claimed from GBGB9817317.2A external-priority patent/GB9817317D0/en
Priority claimed from GBGB9817340.4A external-priority patent/GB9817340D0/en
Priority claimed from GBGB9817360.2A external-priority patent/GB9817360D0/en
Priority claimed from GBGB9817322.2A external-priority patent/GB9817322D0/en
Priority claimed from GBGB9817320.6A external-priority patent/GB9817320D0/en
Priority claimed from GBGB9826173.8A external-priority patent/GB9826173D0/en
Priority claimed from GBGB9826172.0A external-priority patent/GB9826172D0/en
Priority claimed from GBGB9827277.6A external-priority patent/GB9827277D0/en
Priority claimed from GBGB9827341.0A external-priority patent/GB9827341D0/en
Priority claimed from GBGB9828775.8A external-priority patent/GB9828775D0/en
Publication of NO20003960D0 publication Critical patent/NO20003960D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20003960L publication Critical patent/NO20003960L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Salt av paroxetine med en syre valgt fra gruppen bestående av svovelsyre, vinsyre, oksalsyre, fumarsyre, propionsyre, maursyre, glutaminsyre, ravsyre, benzosyre, sitronsyre, salpetersyre, fosforsyre, 4-metylbenzensulfonsyre, hypofosforsyrling, melkesyre og mandelsyrer og glycin er nyttige ved behandling og forebygging av visse CNS-lidelser.Salt of paroxetine with an acid selected from the group consisting of sulfuric, tartaric, oxalic, fumaric, propionic, formic, glutamic, succinic, benzoic, citric, nitric, phosphoric, 4-methylbenzenesulfonic, hypophosphoric and lactic acids and prevention of certain CNS disorders.

NO20003960A 1998-02-06 2000-08-04 Salts of paroxsetine NO20003960L (en)

Applications Claiming Priority (34)

Application Number Priority Date Filing Date Title
GBGB9802657.8A GB9802657D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802645.3A GB9802645D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802664.4A GB9802664D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802661.0A GB9802661D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802656.0A GB9802656D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802654.5A GB9802654D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802644.6A GB9802644D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802638.8A GB9802638D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802659.4A GB9802659D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802646.1A GB9802646D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802698.2A GB9802698D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802640.4A GB9802640D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802655.2A GB9802655D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802639.6A GB9802639D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802653.7A GB9802653D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802658.6A GB9802658D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9802665.1A GB9802665D0 (en) 1998-02-06 1998-02-06 Novel compounds
GBGB9817344.6A GB9817344D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817359.4A GB9817359D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817321.4A GB9817321D0 (en) 1998-08-08 1998-08-08 Novel compound
GBGB9817317.2A GB9817317D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817340.4A GB9817340D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817364.4A GB9817364D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817307.3A GB9817307D0 (en) 1998-08-08 1998-08-08 Novel compound
GBGB9817309.9A GB9817309D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817360.2A GB9817360D0 (en) 1998-08-08 1998-08-08 Novel compounds
GBGB9817322.2A GB9817322D0 (en) 1998-08-10 1998-08-10 Novel compounds
GBGB9817320.6A GB9817320D0 (en) 1998-08-10 1998-08-10 Novel compounds
GBGB9826173.8A GB9826173D0 (en) 1998-11-30 1998-11-30 Novel compounds
GBGB9826172.0A GB9826172D0 (en) 1998-11-30 1998-11-30 Novel compound
GBGB9827277.6A GB9827277D0 (en) 1998-12-11 1998-12-11 Novel compound
GBGB9827341.0A GB9827341D0 (en) 1998-12-11 1998-12-11 Novel compounds
GBGB9828775.8A GB9828775D0 (en) 1998-12-29 1998-12-29 Novel compounds
PCT/GB1999/000380 WO1999040084A1 (en) 1998-02-06 1999-02-05 Salts of paroxetine

Publications (2)

Publication Number Publication Date
NO20003960D0 NO20003960D0 (en) 2000-08-04
NO20003960L true NO20003960L (en) 2000-09-25

Family

ID=27586915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003960A NO20003960L (en) 1998-02-06 2000-08-04 Salts of paroxsetine

Country Status (11)

Country Link
EP (1) EP1053234A1 (en)
JP (1) JP2002505254A (en)
KR (1) KR20010040711A (en)
BG (1) BG104737A (en)
CA (1) CA2319652A1 (en)
EA (1) EA200000815A1 (en)
IL (1) IL137684A0 (en)
NO (1) NO20003960L (en)
PL (1) PL342295A1 (en)
SK (1) SK11812000A3 (en)
WO (1) WO1999040084A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
EP1102764A1 (en) * 1998-08-08 2001-05-30 Smithkline Beecham Plc Paroxetine salts
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
EA200300770A1 (en) * 2001-01-05 2003-10-30 Эли Лилли Энд Компани ANTAGONISTS OF EXCESSING AMINO ACID RECEPTORS
CA2456233A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
KR100672184B1 (en) 2004-09-21 2007-01-19 주식회사종근당 Choline or Choline Derivative Salts of Paroxetine
CN108218844B (en) * 2018-03-08 2021-01-19 合肥科大生物技术有限公司 Memantine paroxetine eutectic salt and preparation method, pharmaceutical composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
HU221921B1 (en) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them

Also Published As

Publication number Publication date
SK11812000A3 (en) 2001-08-06
CA2319652A1 (en) 1999-08-12
WO1999040084A1 (en) 1999-08-12
EP1053234A1 (en) 2000-11-22
NO20003960D0 (en) 2000-08-04
PL342295A1 (en) 2001-06-04
EA200000815A1 (en) 2001-02-26
BG104737A (en) 2001-07-31
KR20010040711A (en) 2001-05-15
IL137684A0 (en) 2001-10-31
JP2002505254A (en) 2002-02-19

Similar Documents

Publication Publication Date Title
NO20003960L (en) Salts of paroxsetine
MXPA03006248A (en) Fumaric acid derivatives as nf-kappab inhibitors.
DK0574313T3 (en) 1,4-disubstituted piperazines for the treatment of central nervous system and neuroendocrine disorders
DE69507199D1 (en) Heterocyclylcarbonyl-substituted benzofuranyl and thiophenylalkane carboxylic acid derivatives
CA2388142A1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
AU8055101A (en) Method for treating fibrotic diseases or other indications ic
HU0003863D0 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
WO2002044142A3 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
MX234582B (en) Method of producing carboxylic acid salts.
DK1236728T3 (en) S-type 2-substituted hydroxy-2-indolidinylbutyric acid ester compounds and process for their preparation
NO20000093D0 (en) (+) - Norcisapride useful for 5-HT3 and 5-HT4-mediated disorders
NO20016201L (en) Tienopyrimidines as phosphodiesterase inhibitors
MX224669B (en) Process for the preparation of carboxylic acid salts from primary alcohols.
WO2002066664A3 (en) Method for the production of d-pantothenic acid and/or salts thereof as adjunct for animal feedstuffs
MY119880A (en) Prucalopride oral solution
NO912475D0 (en) TIAZOLIDINE CARBOXYLIC ACID AMIDE DERIVATIVES WITH ANTIALLERGIC ACTIVITY AND PROCEDURE FOR PREPARING THEREOF.
MXPA02002355A (en) Process for production of naphthyridine 3 carboxylic acid derivatives.
SG77692A1 (en) Process and intermediates for the manufacture of pyridine-2, 3-dicarboxylate compounds
GC0000094A (en) New pseudopolymorphic forms of 2-Ä2-Ä4-bis(4-fluorophenyl)methylÜ-1-piperazinylÜethoxyÜ acetic acid dihydrochloride.
MXPA03008119A (en) Method of producing n-substituted 2,6-dialkyl morpholines.
PL373247A1 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
IN2003CH01297A (en) Method for producing D-pantothenic acid and/or salts thereof as an additive for animal feed
IL157496A0 (en) Method for producing d-pantothenic acid and/or salts thereof as additive to animal feed
DE59501608D1 (en) METHOD FOR PRODUCING POLYASPARAGIC ACID AND / OR POLYASPARAGIC ACID IMIDES
NO20040423L (en) Salts of substituted 1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid derivatives.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application